A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Inclusion Criteria:

• Histologic or cytologic documentation of metastatic melanoma, with BRAFV600 mutation as assessed by cobas® 4800 BRAF V600 Mutation Test. Origin of the primary tumor must be known and may be of skin, mucosal, or acral locations but not of ocular origin.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hematologic and end organ function
• Measurable disease per RECIST v1.1
• For female patients of childbearing potential and male patients with partners of childbearing potential, agreement to use an effective form of contraception and to continue its use for 6 months after discontinuation from the study

Exclusion Criteria:

• Receipt of prior systemic anti-cancer therapy for unresectable, locally advanced or metastatic melanoma
• Receipt of prior MAPK inhibitor pathway agents, including MEK kinase inhibitor and BRAF kinase inhibitor
• Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a major surgical procedure during the course of the study
• Radiotherapy </= 14 days prior to Day 1
• Adverse events from prior anti-cancer therapy that have not resolved to Grade <= 1 except for alopecia
• Current severe, uncontrolled systemic disease excluding cancer
• Known clinically significant liver disease
• Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases
• Any ongoing malignancy other than melanoma
• History or risk of autoimmune disease
• History of idiopathic pulmonary fibrosis, risk of pulmonary toxicity, or evidence of active pneumonitis on screening chest CT scan
• History of HIV or hepatitis C infection
• Active tuberculosis
• Severe infections within 4 weeks prior to Cycle 1 Day 1 or Signs or symptoms of infection within 2 weeks prior to Cycle 1 Day 1
• Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
• Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or anticipation that such a live attenuated vaccine will be required during the study
• History of clinically significant cardiac or pulmonary dysfunction
• Treatment with systemic immunosuppressive medications within 4 weeks prior to Cycle 1 Day 1
• Bisphosphonate therapy for symptomatic hypercalcemia
• Pregnant or lactating women
• Any vemurafenib-specific exclusion criteria